NCT05760586 2024-08-12Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade GliomaDay One Biopharmaceuticals, Inc.Approved for marketing
NCT01425008 2020-08-10Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic MelanomaTakedaPhase 1 Completed149 enrolled 43 charts